0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) + 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) + placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Menopause
Conditions
Menopause, Menopausal Vasomotor Symptoms
Trial Timeline
May 28, 2004 โ May 4, 2005
NCT ID
NCT00184795About 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) + 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) + placebo
0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) + 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) + placebo is a phase 3 stage product being developed by Novo Nordisk for Menopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00184795. Target conditions include Menopause, Menopausal Vasomotor Symptoms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00184795 | Phase 3 | Completed |
Competing Products
20 competing products in Menopause